- Deferasirox in patients with myelodysplastic syndrome and iron overload - Results of the EPIC study - Commenting on the study2013 | First Faculty of Medicine
- Treatment of patients with myelodysplastic syndrome with iron overload oral chelator deferasirox2013 | First Faculty of Medicine
- Experience with chelatation therapy in patients with myelodysplastic syndrome2011 | Faculty of Medicine in Hradec Králové
- A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes2013 | Publication without faculty affiliation
- Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients2021 | First Faculty of Medicine
- Commentary on a study2011 | Publication without faculty affiliation
- Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury2014 | Faculty of Pharmacy in Hradec Králové
- Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity2011 | Faculty of Pharmacy in Hradec Králové
- Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy2021 | Faculty of Science
- Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine2022 | Faculty of Pharmacy in Hradec Králové
- 2,6-Dihydroxybenzaldehyde analogues of the iron chelator salicylaldehyde isonicotinoyl hydrazone: Increased hydrolytic stability and cytoprotective activity against oxidative stress2018 | Faculty of Pharmacy in Hradec Králové
- Cardioprotective Potential of Iron Chelators and Prochelators2019 | Faculty of Pharmacy in Hradec Králové
- Hereditary hyperferritinemia-cataract syndrome in three Czech families: molecular genetic testing and clinical implications2020 | First Faculty of Medicine, Second Faculty of Medicine
- Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome2011 | First Faculty of Medicine
- Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome2011 | Publication without faculty affiliation